MedTrace Logo

Proof-of-Concept Trial of Palonosetron and Olanzapine Without Dexamethasone for the Prevention of CIN

NCT02970643 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 48

Last updated 2016-11-23

No results posted yet for this study

Summary

The purpose of this study is to determine whether Palonosetron and Olanzapine without dexamethasone for the Prevention of moderate risk Chemotherapy-Induced Nausea and vomiting.

Conditions

  • Chemotherapy-induced Nausea and Vomiting

Interventions

DRUG

Olanzapine

Moderate risk chemotherapy induced nausea group in all cancer. D1 Olanzapine 10mg PO D2-3 Olanzapine 10mg PO

DRUG

Palonosetron

Moderate risk chemotherapy induced nausea group in all cancer. D1 Palonosetron 0.25mg IV

Sponsors & Collaborators

  • HK inno.N Corporation

    collaborator INDUSTRY

  • Hee Jun Kim

    lead OTHER

Principal Investigators

  • Heejun Kim, MD.PhD · Associate Professor

Study Design

Allocation
NA
Purpose
PREVENTION
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-07-31
Primary Completion
2017-09-30
Completion
2017-12-31

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02970643 on ClinicalTrials.gov